Side Effect Management | News

Childhood Cancer Survivors May Experience Sooner Aging-Related Disease

March 28th 2025

By Alex Biese

Researchers have found childhood cancer survivors are at risk of experiencing onset of aging-related disease 17.7 years sooner than the general population.

Itolizumab Shows Long-Term Treatment Benefits in Acute GVHD

March 27th 2025

By Ryan Scott

Although itolizumab did not improve response rates at Day 29 for patients with acute GVHD, the therapy showed significant benefits in long-term outcomes.

Dr. Sheri Prentiss on Steps for Lymphedema Screening in Breast Cancer

March 24th 2025

By Dr. Sheri Prentiss

Dr. Sheri Prentiss discusses what steps patients can take to ensure they're being screened for lymphedema prior to starting their breast cancer treatment.

Orca-T Doubles Graft-Versus-Host Disease-Free Survival in Leukemia

March 18th 2025

By Spencer Feldman

Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease across leukemia subtypes.

First Patient Dosed in Trial for Chemotherapy-Induced Neuropathic Pain

March 18th 2025

By Ryan Scott

The first patient has been dosed in a phase 2b trial evaluating the first-in-class agent Halneuron for those with neuropathic pain following chemotherapy.

Expert Explains the Side Effects of Ordspono in R/R Follicular Lymphoma

March 14th 2025

By Dr. Deepa Jagadeesh

Dr. Deepa Jagadeesh discusses Ordspono's potential FDA approval for relapsed/refractory follicular lymphoma, highlighting its manageable toxicity and low CRS rate.

FDA Approves Biosimilars for Cancer-Related Skeletal Events

March 8th 2025

By Alex Biese

The FDA has approved Stoboclo and Osenvelt to address skeletal issues faced by patients with cancer.

Expert Explains Safety of Krazati Regimen For Treating Colorectal Cancer

March 3rd 2025

By Dr. Nataliya Uboha

Krazati plus Erbitux is well tolerated in KRAS G12C-mutant metastatic colorectal cancer, with manageable side effects and less immune suppression.

Immune Checkpoint Inhibitors For Cancer Associated With Psoriasis Risk

March 3rd 2025

By Alex Biese

Researchers have discovered a strong association between the use of immune checkpoint inhibitors for cancer treatment and a risk of new onset psoriasis.

Fractionated Reirradiation is Safe and Feasible in High-Grade Glioma

February 27th 2025

By Ryan Scott

Fractionated reirradiation is safe and feasible, suggesting higher reirradiation dose may be feasible in patients with recurrent high-grade glioma.